Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Immunology | Gastroenterology | Hepatology (Liver, Pancreatic, Gall Bladder) | Infections and Infectious Diseases
Disease Category: Hepatitis C; Chronic
Location: United States, UT

Clinical Trial Details

Overview

Research Study Summary

Hepatitis C

Purpose

A Double-Blind, Randomized, Placebo-Controlled, Single and Multiple-Dose Raging Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Antiviral Activity of GS-9620 in treatment naive Subjects wit chronic Hepatitis C Virus Infection.

Patient Inclusion Criteria:

  • Male or Female ages from 18-65 years old
  • Chronic HCV infection > 6 months
  • Must be HBV surgace antigen negative
  • BMI 18-33 kg/m2

Patient Exclusion Criteria:

  • Co-infection with HBV or HIV
  • Evidence of hepatocellular carcinoma
  • Positive screening for barbituratues, benzodiazepines and opiates

To Learn more
Phase

1

Gender

Both Male and Female

Age

18 to 65 Years

Overall Status

Recruiting

Facility Type

N/A

Contact

Cher Struck, Director Marketing and Recruiting
Lifetree Clinical Research
3838 South 700 East Suite 202
Salt Lake City, UT 84106
Phone: 801-269-8200

View Map

Research Center Information: Lifetree Clinical Research

If you would like to learn more about participating in this research study, please email the trial contact using the form below.

Name:
Address:
City:
State:
Zip/Postal Code:
Country:
Phone:
Email:  
Message:
 
Please leave this field empty.

CW ID: 180841

Date Last Changed: July 19, 2013


DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.